

## Highlights of This Issue 1707

### SPECIAL FEATURES

#### Special Report

- 1709** AACR Celebrates 50 Years of Tobacco Research and Policy  
Roy S. Herbst, Jennifer A. Hobin, and Ellen R. Gritz;  
Writing Committee for the AACR Subcommittee on Tobacco and Cancer

#### Special Commentary

- 1719** It Shouldn't Take Another 50 Years: Accelerating Momentum to End the Tobacco Epidemic  
Howard K. Koh

### CCR Translations

- 1721** Seeing the Forest for the Trees: Kidney Oncogenomes in Relation to Therapeutic Outcomes  
David D. Chism and W. Kimryn Rathmell  
*See related article, p. 1955*
- 1724** Estrogen Receptor Mutations in Breast Cancer—New Focus on an Old Target  
Corrinne V. Segal and Mitch Dowsett  
*See related article, p. 1757*
- 1727** Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?  
Paul A. Bunn Jr, Fred R. Hirsch, and Dara L. Aisner  
*See related article, p. 1946*

### Statistics in Clinical Cancer Research

- 1730** Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials  
Cong Chen and Robert A. Beckman


### CCR Drug Updates

- 1735** Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia  
Varsha Gandhi, William Plunkett, and Jorge E. Cortes



### Molecular Pathways

- 1741** Molecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer  
Silvana Paredes, Lidia Villanova, and Katrin F. Chua

### Review

- 1747** Intratumoral Immunization: A New Paradigm for Cancer Therapy  
 Aurélien Marabelle, Holbrook Kohrt, Christophe Caux, and Ronald Levy

### HUMAN CANCER BIOLOGY

- 1757** Emergence of Constitutively Active Estrogen Receptor- $\alpha$  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer  
 Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Garrett Frampton, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Jaime Ferrer-Lozano, Jose A. Perez-Fidalgo, Massimo Cristofanilli, Henry Gómez, Carlos L. Arteaga, Jennifer Giltane, Justin M. Balko, Maureen T. Cronin, Mirna Jarosz, James Sun, Matthew Hawryluk, Doron Lipson, Geoff Otto, Jeffrey S. Ross, Addie Dvir, Lior Soussan-Gutman, Ido Wolf, Tamar Rubinek, Lauren Gilmore, Stuart Schnitt, Steven E. Come, Lajos Pusztai, Philip Stephens, Myles Brown, and Vincent A. Miller  
*See related article, p. 1724*
- 1768** T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors  
 Rikke Lyngaa, Natasja Wulff Pedersen, David Schrama, Charlotte Albæk Thruue, Dafina Ibrani, Özcan Met, Per thor Straten, Paul Nghiem, Jürgen C. Becker, and Sine Reker Hadrup
- 1779** Downregulation of FOXO3a Promotes Tumor Metastasis and Is Associated with Metastasis-Free Survival of Patients with Clear Cell Renal Cell Carcinoma  
Dong Ni, Xin Ma, Hong-Zhao Li, Yu Gao, Xin-Tao Li, Yu Zhang, Qing Ai, Peng Zhang, Er-Lin Song, Qing-Bo Huang, Yang Fan, and Xu Zhang

# Table of Contents

- 1791** Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer  
Tobias Lange, Mareike Kupfernagel, Daniel Wicklein, Florian Gebauer, Hanna Maar, Kathrin Brügge, Imke Müller, Ronald Simon, Thorsten Schlomm, Guido Sauter, and Udo Schumacher

- 1803** Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting *PIK3CD* and Predicts the Prognosis of Human Glioblastoma



Yu Shi, Cong Chen, Xia Zhang, Qing Liu, Jin-Ling Xu, Hua-Rong Zhang, Xiao-Hong Yao, Tao Jiang, Zhi-Cheng He, Yong Ren, Wei Cui, Chuan Xu, Ling Liu, You-Hong Cui, Shi-Zhu Yu, Yi-Fang Ping, and Xiu-Wu Bian

## CANCER THERAPY: PRECLINICAL

- 1814** Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma



Naoki Kaneko, Keisuke Mitsuoka, Nobuaki Amino, Kentaro Yamanaka, Aya Kita, Masamichi Mori, Sosuke Miyoshi, and Sadao Kuromitsu

- 1823** A Short Treatment with Galactomannan GM-CT-01 Corrects the Functions of Freshly Isolated Human Tumor-Infiltrating Lymphocytes  
Nathalie Demotte, René Bigirimana, Grégoire Wieërs, Vincent Stroobant, Jean-Luc Squifflet, Javier Carrasco, Kris Thielemans, Jean-François Baurain, Patrick Van Der Smissen, Pierre J. Courttoy, and Pierre van der Bruggen

- 1834** Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers  
Pablo D. Garcia, John L. Langowski, Yingyun Wang, Min Chen, Joseph Castillo, Christie Fanton, Marjorie Ison, Tatiana Zavorotinskaya, Yumin Dai, Jing Lu, Xiao-Hong Niu, Stephen Basham, Julie Chan, Jianjun Yu, Michael Doyle, Paul Feucht, Robert Warne, Jamie Narberes, Tiffany Tsang, Christine Fritsch, Audrey Kauffmann, Estelle Pfister, Peter Drucekes, Joerg Trappe, Christopher Wilson, Wooseok Han, Jiong Lan, Gisele Nishiguchi, Mika Lindvall, Cornelia Bellamacina, J. Alex Aycinena, Richard Zang, Jocelyn Holash, and Matthew T. Burger

- 1846** Cross-talk between EphA2 and Braf/CRaf Is a Key Determinant of Response to Dasatinib  
Jie Huang, Wei Hu, Justin Bottsford-Miller, Tao Liu, Hee Dong Han, Behrouz Zand, Sunila Pradeep, Ju-Won Roh, Duangmani Thanappapasr, Heather J. Dalton, Chad V. Pecot, Rajesh Rupaimoole, Chunhua Lu, Bryan Fellman, Diana Urbauer, Yu Kang, Nicholas B. Jennings, Li Huang, Michael T. Deavers, Russell Broaddus, Robert L. Coleman, and Anil K. Sood

## IMAGING, DIAGNOSIS, PROGNOSIS

- 1856** Functional Identification of Cancer-Specific Methylation of *CD01*, *HOXA9*, and *TAC1* for the Diagnosis of Lung Cancer  
John Wrangle, Emi Ota Machida, Ludmila Danilova, Alicia Hulbert, Noreli Franco, Wei Zhang, Sabine C. Glöckner, Mathewos Tessema, Leander Van Neste, Hariharan Easwaran, Kornel E. Schuebel, Julien Licchesi, Craig M. Hooker, Nita Ahuja, Jun Amano, Steven A. Belinsky, Stephen B. Baylin, James G. Herman, and Malcolm V. Brock

- 1865** Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis  
Haeryoung Kim, Burcu Saka, Spencer Knight, Michael Borges, Erica Childs, Alison Klein, Christopher Wolfgang, Joseph Herman, Volkan N. Adsay, Ralph H. Hruban, and Michael Goggins

- 1873** Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma  
Markus Riestler, Lillian Werner, Joaquim Bellmunt, Shamini Selvarajah, Elizabeth A. Guancial, Barbara A. Weir, Edward C. Stack, Rachel S. Park, Robert O'Brien, Fabio A.B. Schutz, Toni K. Choueiri, Sabina Signoretti, Josep Lloreta, Luigi Marchionni, Enrique Gallardo, Federico Rojo, Denise I. Garcia, Yvonne Chekaluk, David J. Kwiatkowski, Bernard H. Bochner, William C. Hahn, Azra H. Ligon, Justine A. Barletta, Massimo Loda, David M. Berman, Philip W. Kantoff, Franziska Michor, and Jonathan E. Rosenberg



# Table of Contents

**1884**    **Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma**

Darrell R. Borger, Lipika Goyal, Thomas Yau, Ronnie T. Poon, Marek Ancukiewicz, Vikram Deshpande, David C. Christiani, Hannah M. Liebman, Hua Yang, Hyeryun Kim, Katharine Yen, Jason E. Faris, A. John Iafrate, Eunice L. Kwak, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blazzkowsky, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Nabeel Bardeesy, Kimberly S. Straley, Sam Agresta, David P. Schenkein, Leif W. Ellisen, David P. Ryan, and Andrew X. Zhu

**1891**    **Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer**

Maria-Gabriela Anitei, Guy Zeitoun, Bernhard Mlecnik, Florence Marliot, Nacilla Haicheur, Ana-Maria Todosi, Amos Kirilovsky, Christine Lagorce, Gabriela Bindea, Dan Ferariu, Mihai Danciu, Patrick Bruneval, Viorel Scripcariu, Jean-Marc Chevallier, Franck Zinzindohoué, Anne Berger, Jérôme Galon, and Franck Pagès

## CANCER THERAPY: CLINICAL

**1900**    **A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothed Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors**

Jordi Rodon, Hussein A. Tawbi, Anne L. Thomas, Ronald G. Stoller, Christian P. Turtschi, Jose Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. Moles, Lin Yang, Camille Granvil, Eunju Hurh, Kristine L. Rose, Dereck D. Amakye, Reinhard Dummer, and Alain C. Mita

**1910**    **Topical Application of a Mucoadhesive Freeze-Dried Black Raspberry Gel Induces Clinical and Histologic Regression and Reduces Loss of Heterozygosity Events in Premalignant Oral Intraepithelial Lesions: Results from a Multicentered, Placebo-Controlled Clinical Trial**



Susan R. Mallery, Meng Tong, Brian S. Shumway, Alice E. Curran, Peter E. Larsen, Gregory M. Ness, Kelly S. Kennedy, George H. Blakey, George M. Kushner, Aaron M. Vickers, Brian Han, Ping Pei, and Gary D. Stoner

**1925**    **Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer**

Johann S. de Bono, Josep M. Piulats, Hardev S. Pandha, Daniel P. Petrylak, Fred Saad, Luis Miguel A. Aparicio, Shahneen K. Sandhu, Peter Fong, Silke Gillissen, Gary R. Hudes, Tao Wang, Judith Scranton, and Michael N. Pollak

**1935**    **Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy**

Cristina Saura, Johanna Bendell, Guy Jerusalem, Shaun Su, Qinhuo Ru, Stefan De Buck, David Mills, Sophie Ruquet, Ana Bosch, Ander Urruticoechea, Joseph T. Beck, Emmanuelle Di Tomaso, David W. Sternberg, Cristian Massacesi, Samit Hirawat, Luc Dirix, and Jose Baselga

## PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

**1946**    **Prediction of Survival in Resected Non-Small Cell Lung Cancer Using a Protein Expression-Based Risk Model: Implications for Personalized Chemoprevention and Therapy**



Kathryn A. Gold, Edward S. Kim, Diane D. Liu, Ping Yuan, Carmen Behrens, Luisa M. Solis, Humam Kadara, David C. Rice, Ignacio I. Wistuba, Stephen G. Swisher, Wayne L. Hofstetter, J. Jack Lee, and Waun K. Hong  
*See related article, p. 1727*

**1955**    **Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy**



Martin H. Voss, A. Ari Hakimi, Can G. Pham, A. Rose Brannon, Ying-Bei Chen, Luis F. Cunha, Oguz Akin, Han Liu, Shugaku Takeda, Sasinya N. Scott, Nicholas D. Succi, Agnes Viale, Nikolaus Schultz, Chris Sander, Victor E. Reuter, Paul Russo, Emily H. Cheng, Robert J. Motzer, Michael F. Berger, and James J. Hsieh  
*See related article, p. 1721*

**1965**    **BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact**




Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzannah C. Boyd, Julie Howler, Robyn Saw, John F. Thompson, Richard F. Kefford, Richard A. Scolyer, and Georgina V. Long



# Table of Contents

- 1978** A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence  
Sheng-Fang Su, André Luís de Castro Abreu, Yoshitomo Chihara, Yvonne Tsai, Claudia Andreu-Vieyra, Siamak Daneshmand, Eila C. Skinner, Peter A. Jones, Kimberly D. Siegmund, and Gangning Liang
- 1990** Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11  
Ross M. Drayton, Ewa Dudzic, Stefan Peter, Simone Bertz, Arndt Hartmann, Helen E. Bryant, and James WF. Catto
- 2001** The Impact of *EGFR* T790M Mutations and *BIM* mRNA Expression on Outcome in Patients with *EGFR*-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial  
Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj, Ana Giménez-Capitán, Jordi Bertran-Alamillo, Niki Karachaliou, Radj Gervais, Bartomeu Massuti, Jia Wei, Teresa Moran, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario Garcia-Campelo, Santiago Viteri, Miquel Taron, Mayumi Ono, Petros Giannikopoulos, Trever Bivona, and Rafael Rosell

## LETTERS TO THE EDITOR

- 2011** Definition of Primary and Secondary Glioblastoma—Letter  
 Peter Werner, Dominik Fritzsche, Heidrun Holland, Manfred Bauer, Wolfgang Krupp, Karl-Titus Hoffmann, Dorothee Saur, Florian Then Bergh, Osama Sabri, and Henryk Barthel
- 2013** Definition of Primary and Secondary Glioblastoma—Response  
Hiroko Ohgaki, Peter Burger, and Paul Kleihues
- 2014** Novel Clinically Relevant Genes in GIST—Letter  
M.A. Pantaleo, M. Nannini, A. Astolfi, and G. Biasco
- 2015** Novel Clinically Relevant Genes in GIST—Response  
Peter Birner and Berthold Streubel


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows a lymph node metastasis from a patient with prostate cancer. Lectin histochemistry with *Helix pomatia* agglutinin shows a decreasing surface presentation of terminal GalNAc- and GlcNAc-residues in lymph node metastasis. In conjunction with this finding, the authors demonstrate that metastatic prostate cancer cells can extravasate in the absence of selectins. For details, see the article by Lange and colleagues on page 1791 of this issue.



# Clinical Cancer Research

**20 (7)**

*Clin Cancer Res* 2014;20:1707-2015.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/20/7>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.